<DOC>
	<DOCNO>NCT00918346</DOCNO>
	<brief_summary>The objective study investigate pharmacodynamics ( express intraocular pressure [ IOP ] ) two formulation tafluprost 0.0015 % eyedrop ( preserve unpreserved ) patient open-angle glaucoma ocular hypertension . The primary aim study show IOP reduction two formulation equivalent end 4 week treatment period .</brief_summary>
	<brief_title>Pharmacodynamics Tafluprost 0.0015 % Eye Drops : Comparison Between Preserved Unpreserved Formulation</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Age 18 year A diagnosis open angle glaucoma ocular hypertension Prior use prostaglandin ( ) Intra ocular pressure 2234 mmHg least one eye Females pregnant , nurse planning pregnancy , females childbearing potential use reliable method contraception Previous participation clinical trial tafluprost investigational drug use contact lenses screen study Presence abnormality significant illness could expect interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Ocular hypertension</keyword>
</DOC>